K. Wnuk-Lipinska

Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

O. Straume, R. Brekken, J. Lorens, 2016 .

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells

H. Ditzel, J. Minna, T. Tan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.

A. Maitra, R. Brekken, J. Lorens, 2018, Cancer research.

Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy

S. Terry, O. Straume, S. Chouaib, 2018, Immunology.

Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models

S. Chouaib, R. Brekken, J. Lorens, 2017 .

AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer

T. Sørlie, T. Tan, J. Thiery, 2020, iScience.

Drivers of EMT and immune evasion

R. Brekken, K. Wnuk-Lipinska, 2017 .

Novel anti-human Axl monoclonal antibodies for improved patient biomarker studies

L. Akslen, J. Lorens, D. Micklem, 2016 .

Abstract 4532A: Development of selective small molecule STING agonists suitable for systemic administration

M. Kujawa, F. Malusa, Ł. Dudek, 2020 .

Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas

J. Edwards, G. Vanhoof, U. Philippar, 2020, Cancer Chemistry.

DISCOVERY OF A NOVEL, POTENTIAL FIRST‐IN‐CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS

J. Edwards, G. Vanhoof, U. Philippar, 2019, Hematological Oncology.

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

J. Minna, R. Brekken, J. Lorens, 2014 .